Get the Stockscreener App
265.00
0.45%
1.20
Krystal Biotech Inc stock is traded at $265.00, with a volume of 234.79K.
It is up +0.45% in the last 24 hours and down -1.53% over the past month.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
See More
Previous Close:
$263.80
Open:
$266.93
24h Volume:
234.79K
Relative Volume:
0.79
Market Cap:
$7.75B
Revenue:
$290.51M
Net Income/Loss:
$89.16M
P/E Ratio:
88.63
EPS:
2.99
Net Cash Flow:
$119.18M
1W Performance:
-2.75%
1M Performance:
-1.53%
6M Performance:
+76.96%
1Y Performance:
+51.24%
1-Day Range:
$257.44
$266.99
1-Week Range:
$253.70
$277.03
52-Week Range:
$122.80
$298.30
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
265.00 | 7.71B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
[144] Krystal Biotech, Inc. SEC Filing - Stock Titan
Segall Bryant & Hamill LLC Lowers Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech at TD Cowen Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Kathryn Romano Sells 750 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Daniel Janney Sells 11,803 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Daniel Janney sells Krystal Biotech (KRYS) shares worth $3.25 million - Investing.com
Krystal Biotech (KRYS) CAO sells shares and receives fresh stock awards - Stock Titan
Krystal Biotech (KRYS) R&D chief logs new awards, PSU vesting and tax trades - Stock Titan
Krystal Biotech (NASDAQ: KRYS) CEO reports new equity awards and tax share surrenders - Stock Titan
Alta Bioequities linked to Krystal Biotech (KRYS) director sells 11,803 shares - Stock Titan
Krystal Biotech, Inc. $KRYS Position Increased by William Blair Investment Management LLC - MarketBeat
TD Asset Management Boosts Stake in Krystal Biotech - National Today
TD Asset Management Inc Boosts Position in Krystal Biotech, Inc. $KRYS - MarketBeat
KRYS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kathryn Romano sells 12,500 KRYS shares (NASDAQ: KRYS); 750 more vest - Stock Titan
Krystal Biotech, Inc. (KRYS) Stock Analysis: A Promising Genetic Medicine Leader with 13.63% Potential Upside - DirectorsTalk Interviews
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Krystal Biotech (KRYS) Is Up 5.6% After Stronger 2025 Profitability And EPS Growth Has The Bull Case Changed? - Sahm
Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224 - Yahoo Finance
Krystal Biotech director Janney sells shares worth $10.1 million - Investing.com
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 700 Shares - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 37,895 Shares - MarketBeat
Daniel Janney Sells 7,741 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech director Janney sells shares worth $10.1 million By Investing.com - Investing.com Canada
Krystal Biotech Director Janney Daniel Sells Over $16 Million in Company Stock - TradingView
Vanguard Group Inc. Cuts Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Assessing Krystal Biotech (KRYS) Valuation After Earnings Beat And Profitability Milestone - simplywall.st
(KRYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Krystal Biotech (NASDAQ:KRYS) Given New $284.00 Price Target at Guggenheim - MarketBeat
Guggenheim Raises Price Target for Krystal Biotech (KRYS) to $28 - GuruFocus
Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates - MSN
Risk On: Can Krystal Biotech Inc weather a recessionJuly 2025 Market Mood & Growth Focused Entry Reports - baoquankhu1.vn
Insider Unloading: Dino A Rossi Sells Options, Realizes $5.04M - Benzinga
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference - Bitget
Krystal Biotech execs to host TD Cowen fireside chat March 3 - Stock Titan
Krystal Biotech’s KB707 RMAT Win Opens New Lung Cancer Chapter - Yahoo Finance
Krystal Biotech Insider Sold Shares Worth $4,953,694, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech RMAT Win Shifts Focus To Broader Gene Therapy Pipeline - simplywall.st
Krystal Biotech (NASDAQ:KRYS) Director Sells $4,953,719.50 in Stock - MarketBeat
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million - Investing.com
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million By Investing.com - Investing.com India
Krystal Biotech Director Dino A. Rossi Sells Shares - TradingView
Director at Krystal Biotech (NASDAQ: KRYS) sells 18,950 shares - Stock Titan
Krystal Biotech, Inc. (KRYS) Stock Analysis: An Investor's Guide To A Promising 17% Upside - DirectorsTalk Interviews
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - The Motley Fool
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 - Yahoo Finance
Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating - Finviz
Aug EndMonth: What is the long term forecast for Giftify Inc stockInsider Selling & Expert Curated Trade Ideas - baoquankhu1.vn
Analysts Offer Predictions for Krystal Biotech Q2 Earnings - MarketBeat
Krystal Biotech, Inc. $KRYS Shares Sold by Aberdeen Group plc - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Trading Down 6.9%Here's Why - MarketBeat
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):